A Phase I Clinical Trial on the safety of KRN125 in breast cancer patients
Latest Information Update: 20 May 2022
Price :
$35 *
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Early breast cancer
- Focus Adverse reactions
- Sponsors Kyowa Kirin
- 17 Dec 2021 New trial record